Evommune (EVMN) vs Vicore Pharma AB (VCRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Vicore Pharma AB is the larger company by market cap ($245.9 million vs $221.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVMN | VCRE |
|---|---|---|
| Share price | $6.10 | $8.73 |
| Market cap | $221.38M | $245.88M |
| 1-day change | -1.93% | +0.81% |
| YTD return | -63.67% | — |
| EPS (TTM) | $-3.75 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.20 | $17.80 |
| 52-week low | $6.06 | $7.88 |
| Distance from 52-week high | -81.63% | -50.96% |
| Analyst consensus | buy | none |
| Avg. price target upside | +295.57% | +279.84% |
| Average volume | 697.98K | 16.24K |
| Shares outstanding | 36.29M | 28.16M |
| Employees | 48 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Evommune
EVMN stock →Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Vicore Pharma AB
VCRE stock →Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 46 employees
EVMN vs VCRE FAQ
Which is bigger, Evommune or Vicore Pharma AB?
Vicore Pharma AB (VCRE) is larger, with a market capitalization of $245.88M compared with $221.38M for Evommune (EVMN).
Are Evommune and Vicore Pharma AB in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.